Efficacy of Chinese herbal medicine for tPA thrombolysis in experimental stroke: A systematic review and meta-analysis.

Abstract

BACKGROUND:

Tissue-type plasminogen activator (tPA) remains the sole FDA approved thrombolytic drug for ischemic stroke. But delayed thrombolytic therapy with tPA may increase the risk of hemorrhagic transformation. Many Chinese herbal medicines have been used as tPA helpers to enhance the capacity of tPA and minimize the risk of hemorrhagic transformation. The efficacy of Chinese herbal medicines on tPA thrombolysis is not systematically analyzed.

METHODS:

We searched the following three databases up to January 2022: Web of Science, PubMed, and Scopus. Studies that reported the efficacy and safety of Chinese herbal medicines on tPA thrombolysis in experimental stroke were included. The efficacy outcomes were neurological score and infarct volume, the safety outcomes were cerebral hemorrhage and blood brain barrier (BBB) damage. We used the checklist of CAMARADES to assess the quality of included studies. Standardized mean difference (SMD) with 95% confidence intervals were used to assess all the outcomes. Subgroup analyses were performed to explore the sources of heterogeneity. Trim and fill method and Egger's test were used to assess the potential publication bias. Sensitivity analyses were used to identify the stability of the results.

RESULTS:

A total of nine studies including 11 Chinese herbal medicines fulfilled the inclusion criteria and were subsequently analyzed. The pooled data demonstrated that Chinese herbal medicines improved neurological score (2.23 SMD, 1.42-3.04), infarct volume (1.08 SMD, 0.62-1.54), attenuated cerebral hemorrhage (1.87 SMD, 1.34-2.4), and BBB dysfunction (1.9 SMD, 1.35-2.45) following tPA thrombolysis in experimental stroke. Subgroup analysis indicated that the route of drug delivery, dosage of tPA, and stroke model used may be factors inducing heterogeneity and influencing the efficacy.

CONCLUSION:

Treatment with Chinese herbal medicines significantly improved neurological score and infarct volume, reduced cerebral hemorrhage and BBB damage after tPA thrombolysis. This study supports Chinese herbal medicine as an adjuvant therapy in reducing the side effects of tPA thrombolysis after acute ischemic stroke. The results should be interpreted with more caution since this article was based on animal studies.

• Authors: Yang Ye, Yu-Tian Zhu, Xi-Yan Xin, Jia-Cheng Zhang, Hao-Lin Zhang, Dong Li
• Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology (Phytomedicine) Vol. 100 Pg. 154072 (Jun 2022) ISSN: 1618-095X [Electronic] Germany
• PMID: 35349833 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
• Copyright: Copyright © 2022 Elsevier GmbH. All rights reserved.

Chemical References

• Drugs, Chinese Herbal
• Fibrinolytic Agents
• Tissue Plasminogen Activator

Topics

• Animals
• Cerebral Hemorrhage (drug therapy)
• Drugs, Chinese Herbal (pharmacology, therapeutic use)
• Fibrinolytic Agents (therapeutic use)
• Infarction (chemically induced, drug therapy)
• Ischemic Stroke
• Stroke (drug therapy, etiology)
• Thrombolytic Therapy (adverse effects, methods)
• Tissue Plasminogen Activator (adverse effects)